Arcus Biosciences Inc (RCUS)
16.05
+0.35
(+2.23%)
USD |
NYSE |
May 06, 11:52
Arcus Biosciences Price to Book Value: 3.157 for May 6, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 3.088 |
| May 02, 2024 | 3.048 |
| May 01, 2024 | 3.048 |
| April 30, 2024 | 2.995 |
| April 29, 2024 | 3.074 |
| April 26, 2024 | 3.058 |
| April 25, 2024 | 2.897 |
| April 24, 2024 | 3.035 |
| April 23, 2024 | 3.048 |
| April 22, 2024 | 2.887 |
| April 19, 2024 | 2.870 |
| April 18, 2024 | 2.919 |
| April 17, 2024 | 2.919 |
| April 16, 2024 | 3.121 |
| April 15, 2024 | 3.204 |
| April 12, 2024 | 3.261 |
| April 11, 2024 | 3.400 |
| April 10, 2024 | 3.290 |
| April 09, 2024 | 3.432 |
| April 08, 2024 | 3.338 |
| April 05, 2024 | 3.410 |
| April 04, 2024 | 3.397 |
| April 03, 2024 | 3.479 |
| April 02, 2024 | 3.485 |
| April 01, 2024 | 3.635 |
| Date | Value |
|---|---|
| March 28, 2024 | 3.713 |
| March 27, 2024 | 3.582 |
| March 26, 2024 | 3.275 |
| March 25, 2024 | 3.239 |
| March 22, 2024 | 3.231 |
| March 21, 2024 | 3.391 |
| March 20, 2024 | 3.440 |
| March 19, 2024 | 3.402 |
| March 18, 2024 | 3.387 |
| March 15, 2024 | 3.733 |
| March 14, 2024 | 3.603 |
| March 13, 2024 | 3.747 |
| March 12, 2024 | 3.666 |
| March 11, 2024 | 3.739 |
| March 08, 2024 | 3.538 |
| March 07, 2024 | 3.524 |
| March 06, 2024 | 3.808 |
| March 05, 2024 | 3.694 |
| March 04, 2024 | 3.739 |
| March 01, 2024 | 3.756 |
| February 29, 2024 | 3.762 |
| February 28, 2024 | 3.766 |
| February 27, 2024 | 3.969 |
| February 26, 2024 | 3.867 |
| February 23, 2024 | 3.841 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.465
Minimum
Jun 26 2019
14.00
Maximum
Jun 02 2020
3.249
Average
2.762
Median
Price to Book Value Benchmarks
| Gilead Sciences Inc | 4.603 |
| Catalyst Pharmaceuticals Inc | 4.491 |
| Integra Lifesciences Holdings Corp | 1.169 |
| Vertex Pharmaceuticals Inc | 5.900 |
| Adverum Biotechnologies Inc | 2.539 |
Price to Book Value Related Metrics
| PS Ratio | 10.15 |
| PEG Ratio | -0.3346 |
| Price | 16.05 |
| Earnings Yield | -25.86% |
| Market Cap | 1.458B |
| PEGY Ratio | -0.3346 |